Trial Profile
Phase I/II trial of E6-TCR as a monotherapy and in combination with a checkpoint inhibitor in HPV-16 associated solid tumors
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2015
Price :
$35
*
At a glance
- Drugs E6 TCR (Primary)
- Indications Anal cancer; Cervical cancer; Head and neck cancer; Penile cancer; Vulvovaginal cancer
- Focus Adverse reactions
- 06 Oct 2015 New trial record
- 01 Oct 2015 According to a media release, Kite Pharma expects to file an IND for this company-sponsored trial in the first half of 2016.